Cardiovascular risk assessment in the treatment of nonalcoholic steatohepatitis: a secondary analysis of the MOZART trial

BACKGROUND: Nonalcoholic steatohepatitis (NASH) is associated with increased cardiovascular risk and mortality. No US Food and Drug Administration (FDA) approved therapies for NASH are available; clinical trials to date have not yet systematically assessed for changes in cardiovascular risk. This st...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Therap Adv Gastroenterol
Päätekijät: Lin, Steven C., Ang, Brandon, Hernandez, Carolyn, Bettencourt, Ricki, Jain, Rashmi, Salotti, Joanie, Richards, Lisa, Kono, Yuko, Bhatt, Archana, Aryafar, Hamed, Lin, Grace Y., Valasek, Mark A., Sirlin, Claude B., Brouha, Sharon, Loomba, Rohit
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2016
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4749859/
https://ncbi.nlm.nih.gov/pubmed/26929777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15621232
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia